{
    "Trade/Device Name(s)": [
        "Q-Pad Test System",
        "Q-Pad Kit",
        "Q-Pad A1c Test"
    ],
    "Submitter Information": "Qurasense",
    "510(k) Number": "K231465",
    "Predicate Device Reference 510(k) Number(s)": [
        "K141944"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LCP",
        "QZG"
    ],
    "Summary Letter Date": "December 6, 2023",
    "Summary Letter Received Date": "May 19, 2023",
    "Submission Date": "May 19, 2023",
    "Regulation Number(s)": [
        "21 CFR 864.7470",
        "21 CFR 862.1675"
    ],
    "Regulation Name(s)": [
        "Glycosylated hemoglobin assay",
        "Menstrual Blood Collection Device"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Hemoglobin A1c"
    ],
    "Specimen Type(s)": [
        "Menstrual blood"
    ],
    "Specimen Container(s)": [
        "Q-Pad menstrual pad",
        "filter paper (Q-Strip)"
    ],
    "Instrument(s)/Platform(s)": [
        "Beckman Coulter AU480"
    ],
    "Method(s)/Technology(ies)": [
        "Laboratory analysis using Beckman Coulter A1c reagents"
    ],
    "Methodologies": [
        "Quantitative measurement of Hemoglobin A1c"
    ],
    "Submission Type(s)": [
        "Specimen collection device",
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for Qurasense Q-Pad Test System for at-home menstrual blood collection and laboratory HbA1c measurement",
    "Indications for Use Summary": "For collection of menstrual blood samples by women 18+ for laboratory quantitative measurement of HbA1c to monitor long-term blood glucose control in diabetes; not for diagnosis or screening.",
    "fda_folder": "Hematology"
}